

OMB APPROVAL	
OMB Number:	3235-0287
Expires:	December 31, 2014
Estimated average burden hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> Scibetta James S  (Last) (First) (Middle) C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300  (Street) PARSIPPANY CO 07054  (City) (State) (Zip)	<b>2. Issuer Name and Ticker or Trading Symbol</b> Pacira Pharmaceuticals, Inc. [PCRX]	<b>5. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) SVP, Chief Financial Officer
	<b>3. Date of Earliest Transaction (Month/Day/Year)</b> 02/06/2015	
		<b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/06/2015		M		15,000	A	\$ 1.61	20,230 <sup>(7)</sup>	D	
Common Stock	02/06/2015		S <sup>(1)</sup>		4,293	D	\$ 110.17 <sup>(2)</sup>	15,937	D	
Common Stock	02/06/2015		S <sup>(1)</sup>		5,904	D	\$ 111.11 <sup>(3)</sup>	10,033	D	
Common Stock	02/06/2015		S <sup>(1)</sup>		3,103	D	\$ 111.98 <sup>(4)</sup>	6,930	D	
Common Stock	02/06/2015		S <sup>(1)</sup>		1,700	D	\$ 112.91 <sup>(5)</sup>	5,230	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 1.61	02/06/2015		M			15,000	(6)	09/02/2020	Common Stock	15,000	\$ 0	38,250	D	

**Explanation of Responses:**

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$109.58 to \$110.57, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 5.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$110.59 to \$111.58, inclusive.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$111.59 to \$112.58, inclusive.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$112.63 to \$113.17, inclusive.
- The option vested as to 50% of the options on September 2, 2010 and vests as to the remaining options in successive equal monthly installments for the subsequent 24 months. The options become exercisable, to the extent vested, from and after the issuer's initial public offering.
- Includes 230 shares of common stock acquired under the issuer's employee stock purchase plan in December 2014.

/s/ James Scibetta                      02/09/2015  
 \*\* Signature of Reporting              Date  
 Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**